Skip to content

Ketamine: all studies

Page 159 of 449: studies 1,581 to 1,590 of 4,486, newest first. Back to the ketamine overview

Research

Change in Negative Affective Bias following a Single Ketamine Treatment for Treatment-Resistant Depression

Depression and Anxiety August 19, 2023 Anna J. Harvey, Stevan Nikolin, Nicholas Chand et al. 4 citations

Ketamine has recently emerged as a highly effective new treatment for people with treatment-resistant depression with rapid antidepressant effects. However, these effects are often short lasting, and the potential cognitive mechanisms underlying the therapeutic effects, such as effects on emotional processing bias, remain poorly understood. In the present study, we explored potential changes in...

New Frontiers in Ketamine Research: From Mechanisms of Action to Novel Psychiatric Treatment Approaches

American Journal of Psychiatry and Neuroscience August 17, 2023 Marcus C. Rosenhagen, Julien Elowe, Alberto Forte et al.

Ketamine, initially developed as a safer alternative to phencyclidine, has emerged as a groundbreaking treatment in psychiatric practice. It gained popularity after its approval by the FDA in 1970 for its analgesic properties and ability to induce altered consciousness while maintaining vital functions. In the 1990s, researchers discovered its rapid and potent antidepressant effects, especially...

The effect of ketamine on affective modulation of the startle reflex and its resting-state brain correlates

Scientific Reports August 16, 2023 Zümrüt Duygu Sen, Tara Chand, Lena Vera Danyeli et al.

Ketamine is a rapid-acting antidepressant that also influences neural reactivity to affective stimuli. However, the effect of ketamine on behavioral affective reactivity is yet to be elucidated. The affect-modulated startle reflex paradigm (AMSR) allows examining the valence-specific aspects of behavioral affective reactivity. We hypothesized that ketamine alters the modulation of the startle...

Resveratrol plays Neuroprotective role on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice.

Neuroscience Letters August 14, 2023 Alireza Farkhakfar, Shahin Hassanpour, Morteza Zendehdel

This study aimed to determine effects of the resveratrol on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice. Twenty-four male mice were allocated into four experimental groups as control, ketamine (20mg/kg), resveratrol (80mg/kg) and co-administration of the ketamine (20mg/kg) + resveratrol (80mg/kg). Mice were received resveratrol for 30 days and ketamine was used...

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.

CNS Drugs August 9, 2023 Meredith Castro, Samuel T. Wilkinson, Rayan K. Al Jurdi et al.

Background: Treatment-resistant depression (TRD) is a chronic illness requiring long-term treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of patients with TRD, including SUSTAIN-1 (NCT02493868) and SUSTAIN-3 (NCT02782104). This subgroup analysis of SUSTAIN-3 evaluated patients with TRD who received a second induction (IND) and maintenance treatment with ESK...

Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression

Frontiers in Neuroscience August 8, 2023 August P. M. Lullau, E. Haga, E. Ronold et al.

Concurrent with recent insights into the neuroprogressive nature of depression, ketamine shows promise in interfering with several neuroprogressive factors, and has been suggested to reverse neuropathological patterns seen in depression. These insights come at a time of great need for novel approaches, as prevalence is rising and current treatment options remain inadequate for a large number of...

Lateral Septal Circuits Govern Schizophrenia-Like Effects of Ketamine on Social Behavior

bioRxiv Preprint Server August 8, 2023 Ruixiang Wang, Zeru Peterson, Nagalakshmi Balasubramanian et al. 1 citation preprint

Schizophrenia is marked by poor social functioning that can have a severe impact on quality of life and independence, but the underlying neural circuity is not well understood. Here we used a translational model of subanesthetic ketamine in mice to delineate neural pathways in the brain linked to social deficits in schizophrenia. Mice treated with chronic ketamine (30 mg/kg/day for 10 days)...

DOI: 10.1101/2023.08.08.552372 (opens in new tab) Full text (opens in new tab) Schizophrenia-like symptoms Psychiatric disorder Mental illness Neurobiology +14

Suicidal ideation and suicide attempt following ketamine prescription in patients with treatment-resistant depression: a nation-wide cohort study

Research Square August 7, 2023 Rong Xu, Yiheng Pan, Maria P Gorenflo et al. preprint

Abstract Ketamine, including esketamine, is an effective treatment for patients with treatment-resistant depression (TRD); however, its long-term efficacy in real-world populations remains poorly characterized. This is a retrospective cohort study using TriNetX US Collaborative Network, a platform aggregating electronic health records (EHRs) data from 93 million patients from 56 health care...